{"id":943,"date":"2022-09-16T18:35:19","date_gmt":"2022-09-16T18:35:19","guid":{"rendered":"https:\/\/omnisurgical.com\/international\/?p=943"},"modified":"2024-02-15T15:33:28","modified_gmt":"2024-02-15T15:33:28","slug":"sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-european-society-of-cataract-and-refractive-surgery-annual-meeting","status":"publish","type":"post","link":"https:\/\/omnisurgical.com\/international\/blog\/2022\/09\/16\/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-european-society-of-cataract-and-refractive-surgery-annual-meeting\/","title":{"rendered":"Sight Sciences OMNI\u00ae Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting"},"content":{"rendered":"
\n
<\/p>\n
\n
\n
<\/p>\n
<\/p>\n
<\/p>\n
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\tPDF Version<\/a>
\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t<\/div>\n
\n
<\/div>\n

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone use<\/h3>\n

\t\t\t\t\t\t\t
<\/p>\n

MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, Italy on Friday, September 16 through Tuesday, September 20.
<\/p>\n

At Sight Sciences Booth A22 in Hall 4 at the Milano Convention Centre, ESCRS attendees will also have the opportunity to engage in peer-to-peer discussions with four glaucoma physicians and participate in hands-on demonstrations with the OMNI Surgical System – an implant-free procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm\u2019s canal and the collector channels.<\/p>\n


<\/p>\n

\u201cGlobally, there are significant drawbacks associated with eyedrop-based glaucoma polypharmacy in terms of both cost to the healthcare system and poor patient compliance,\u201d said Paul Badawi, CEO and co-founder of Sight Sciences. He continued, \u201cWe are honored to witness the growing adoption of the OMNI Surgical System in both combination cataract procedures as well as in standalone use.\u201d<\/p>\n


<\/p>\n

\n\t\t\t\t\t\t\t\t\tPoster Presentations<\/strong>\n\t\t\t\t\t\t\t\t<\/p>\n


<\/p>\n

    \n
  1. Intraocular Pressure (IOP) Fluctuations and Visual Field Status: Fluctuation Suppression with Combined Canaloplasty and Trabeculotomy in Open-Angle Glaucoma (OAG) by Michael Greenwood, MD<\/li>\n
  2. Outcomes Of Canaloplasty and Trabeculotomy in Glaucomatous Eyes with Previous Trabecular Micro-Bypass Implantation and Uncontrolled on Medication by Daniel Terveen, MD; Michael Greenwood, MD<\/li>\n
  3. A Prospective, 36-Month Evaluation of Subjects with Mild to Moderate Open-Angle Glaucoma Treated with the OMNI Surgical System as Standalone Procedure by Karsten Klabe, MD; Andreas Fricke, MD<\/li>\n
  4. Omni Surgical System: Preliminary Results from a Systematic Review Evaluating the Treatment of Open-Angle Glaucoma by Dan Lindfield, MD<\/li>\n
  5. Long Term Effect of Ab-Interno Canaloplasty with or without Cataract Extraction (CE) on Intraocular Pressure (IOP) and Use of IOP Lowering Medications in Patients with Open-Angle Glaucoma (OAG) by Simon Ondrejka, Norbert Koerber<\/li>\n
  6. Real World Evaluation of Canaloplasty and Trabeculotomy Combined with Cataract Surgery in Open-Angle Glaucoma (OAG): A Retrospective, Multicenter, 12 Month Study (ROMEO II) by James Murphy, MD<\/li>\n
  7. OMNI in Open-Angle Glaucoma Treatment: A 42-Month Interim Follow-Up by Iwona Grabska-Liberek, MD, PhD; Anna M. Koziorowska, MD; Joanna Wereszczy\u0144ska, MD; Julita Majszyk-Ionescu, MD<\/li>\n


    \n\t\t\t\t\t\t\t\t\t<\/ol>\n

    \n\t\t\t\t\t\t\t\t\t\tOMNI Experts at ESCRS (Booth A22\/Hall 4) <\/strong>
    \n\t\t\t\t\t\t\t\t\t\tFriday, September 16, 2022<\/p>\n


    <\/p>\n